Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-13

Whoever is selling, please keep selling. The $22 million in cash within the company can just collect interest and the company will just get cheaper to buy with the current market cap of $13.5 million. Lower overheads going forward and still something left for the company to work towards.

I understand the disappointment for many shareholders here but the market is cruel and Biotech is very risky in general. But there's value here emotions aside. Might take a while for a bounce it seems but a much safer bet here with the cash backing.